COMMUNIQUÉS West-GlobeNewswire

GENFIT LAUNCHES AN OFFERING OF BONDS CONVERTIBLE INTO NEW SHARES AND/OR EXCHANGEABLE FOR EXISTING SHARES ("OCEANEs") DUE 2022 FOR AN AMOUNT OF APPROXIMATELY €150 MILLION

11/10/2017 - 07:32

This press release may not be published, forwarded or distributed, directly or indirectly in the United States of America, Canada, Australia or Japan. This press release does not constitute or form part of any offer or [...]

GENFIT : Information financière du troisième trimestre 2017

11/10/2017 - 07:30

GENFIT : Information financière du troisième trimestre 2017 (Données non auditées établies selon les normes IFRS) Trésorerie et équivalents de trésorerie s'élevant à 113,8 millions d'euros au 30 septembre 2017 Chiffre d [...]

GENFIT: Third quarter 2017 financial information

11/10/2017 - 07:30

GENFIT: Third quarter 2017 financial information (Unaudited financial information under IFRS) Cash and cash equivalents of €113.8 million at September 30, 2017 Revenues for the first nine months of 2017 of €91 thousand [...]

Merus to Participate in the BIO Investor Forum

10/10/2017 - 22:08

UTRECHT, The Netherlands, Oct. 10, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that Ton Logtenberg [...]

Vistin Pharma ASA : Call for extraordinary general meeting

10/10/2017 - 16:03

Oslo, Norway, 10 October 2017 Vistin Pharma ASA (OSE: VISTIN), please find attached the call for the extraordinary general meeting in Vistin Pharma, to be held on 2 November at 10:00 CET at Østensjøveien 27, Oslo. The [...]

CrownBio Enhances Its European Capabilities with New Generation of Innovative Translational Models for Obesity and Diabetes

10/10/2017 - 15:45

SANTA CLARA, Calif., Oct. 10, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience , a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company [...]

Patient Entrepreneur Finalists Announced for the 2017 Lyfebulb-Novo Nordisk Innovation Summit and Award

10/10/2017 - 15:23

The Summit & Award recognizes and empowers international Patient Entrepreneurs with big ideas that disrupt the future of diabetes management NEW YORK, Oct. 10, 2017 (GLOBE NEWSWIRE) -- The finalists for the 2017 [...]

Abiomed Second Quarter Fiscal 2018 Earnings and Conference Call Notification

10/10/2017 - 14:00

DANVERS, Mass., Oct. 10, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc . (NASDAQ:ABMD) announced that on Thursday, October 26, 2017, the Company will release financial results for the second quarter of fiscal 2018. The Company [...]

Chiffre d'affaires d'Abiomed pour le second trimestre 2018 et notification de conférence téléphonique

10/10/2017 - 14:00

DANVERS, Massachusetts, le 10 octobre 2017 (GLOBE NEWSWIRE) - Abiomed, Inc. (NASDAQ : ABMD) a annoncé qu'elle communiquera ses résultats financiers pour le deuxième trimestre de l'exercice fiscal de 2018 le jeudi 26 [...]

ObsEva SA Announces $60.0 Million Private Placement with Existing and New Investors

10/10/2017 - 14:00

Geneva, Switzerland and Boston, MA - 10 October, 2017 - ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions [...]

The IPO of Terveystalo Plc has been oversubscribed and the listing will be completed as planned

10/10/2017 - 14:00

TERVEYSTALO PLC STOCK EXCHANGE RELEASE October 10, 2017 at 3:00 p.m. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, THE HONG KONG SPECIAL [...]

Arix Bioscience notes positive Phase I clinical and non-clinical data from Amplyx for the treatment of life-threatening fungal infections

10/10/2017 - 13:00

Arix Bioscience notes positive Phase I clinical and non-clinical data from Amplyx for the treatment of life-threatening fungal infections LONDON, 10 October 2017: Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience"), a [...]

Apricus Biosciences to Present at the 2017 BIO Investor Forum

10/10/2017 - 13:00

SAN DIEGO, Oct. 10, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Richard Pascoe, Chief [...]

ESPERITE (ESP) : EUR 1.1 million of new funding provided by L1 Capital to support Esperite's strategy, commercial activities and development of innovative technologies

10/10/2017 - 08:52

Amsterdam, The Netherlands - 10 October 2017 As of today, EUR 2,700,000 of notes out of the total commitment amounting to EUR 9 million have been converted into shares and EUR 112,500 of warrants out of a total [...]

Helsinn announces its support for the International Fellowship Program (IFP), a joint project founded by the Society for Translational Oncology (STO) and Chinese Society of Clinical Oncology (CSCO)

10/10/2017 - 08:30

Helsinn announces its support for the International Fellowship Program (IFP), a joint project founded by the Society for Translational Oncology (STO) and Chinese Society of Clinical Oncology (CSCO) Lugano, Switzerland, [...]

Solon Eiendom ASA : Primary insider notification

10/10/2017 - 08:30

(Oslo, Norway, 09 October 2017) Solon Eiendom ASA Chairman of the Board Simen Thorsen (through his wholly owned company Hortulan AS) has today bought 18,306 shares in Solon Eiendom ASA at a price of NOK 18.7198 per [...]

Immunicum AB (publ) Announces Appointment of Sharon Longhurst as Head of CMC

10/10/2017 - 08:00

Press Release 10 October 2017 Immunicum AB (publ) Announces Appointment of Sharon Longhurst as Head of CMC Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel, immune-priming [...]

Akcea Therapeutics' Volanesorsen Receives Promising Innovative Medicine (PIM) Status for the Treatment of Familial Chylomicronaemia Syndrome (FCS)

10/10/2017 - 08:00

LONDON, Oct. 10, 2017 (GLOBE NEWSWIRE) -- Akcea Therapeutics United Kingdom (UK) today announced that volanesorsen has been granted a Promising Innovative Medicine (PIM) Designation by the Medicines and Healthcare [...]

Nicox et pSivida : accord de collaboration stratégique en vue du développement d'un médicament à libération prolongée pour réduire la pression intraoculaire chez les patients atteints de glaucome

10/10/2017 - 07:30

Communiqué de presse Nicox et pSivida : accord de collaboration stratégique en vue du développement d'un médicament à libération prolongée pour réduire la pression intraoculaire chez les patients atteints de glaucome [...]